The ARHGEF10 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This product comprises a heterogeneous pool of cells carrying diverse loss-of-function alterations at the ARHGEF10 locus, enabling robust assessment of gene function while avoiding the artifacts associated with clonal selection. CRISPR/Cas9-mediated gene disruption leads to functional ablation of the ARHGEF10-encoded Rho guanine nucleotide exchange factor, providing a versatile tool for dissecting ARHGEF10-dependent processes in a physiologically relevant epithelial cancer background.
The parental A-549 cell line is a well-characterized human lung adenocarcinoma model, originally isolated from a 58-year-old Caucasian male. These cells exhibit an alveolar type II-like epithelial morphology and maintain key adenocarcinoma features, including adherent growth, invasive capacity, and responsiveness to growth factor signaling. A-549 cells are widely utilized in cancer research for investigating oncogenic pathways, metastatic mechanisms, and drug sensitivity. The polyclonal knockout population is generated directly from this established line, preserving the native genetic background while introducing ARHGEF10 disruption, thereby allowing direct and meaningful comparisons with wild-type A-549 cells in functional assays.
ARHGEF10 functions as a specific guanine nucleotide exchange factor for Rho family GTPases, primarily RhoA, RhoB, and RhoC, catalyzing their activation by GDP/GTP exchange. Upstream regulators including integrin receptors, epidermal growth factor receptor (EGFR), and mechanical stress stimulate ARHGEF10, which in turn activates downstream signaling through the RhoA/ROCK1/LIMK1/cofilin (CFL1) axis. ARHGEF10 also interacts with microtubules and ??-tubulin, bridging the actin and microtubule cytoskeletal networks. This signaling cascade promotes phosphorylation and inactivation of cofilin, leading to stabilization of filamentous actin (F-actin) stress fibers and maturation of focal adhesions, thereby governing cell morphology, adhesion, and migration.
In the A-549 cellular context, ARHGEF10 knockout impairs RhoA activation and attenuates downstream ROCK signaling, resulting in reduced actin stress fiber formation and diminished focal adhesion maturation. Consequently, ARHGEF10-deficient A-549 cells display decreased migratory and invasive capacities, which are critical attributes in cancer metastasis. The polyclonal nature of this knockout model mirrors the genetic heterogeneity found in tumors, providing a more realistic system for examining the role of Rho GTPase signaling in lung adenocarcinoma progression and for evaluating the dependency of invasive behavior on ARHGEF10 function.
These cells are optimized for Rho GTPase signaling studies, cell migration and invasion assays, and anti-metastatic drug target validation. Compatible experimental approaches include Western blotting, RhoA activation GST-Rhotekin pull-down, immunofluorescence for F-actin and vinculin, transwell migration, wound healing, and RT-qPCR. They serve as a genetic ablation model for ARHGEF10 functional analysis and are useful in screens for cytoskeletal modulators. For further technical information, contact Ascent Research.
